BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
FRA:BRM - Deutsche Boerse Ag - US1101221083 - Common Stock - Currency: EUR
Taking everything into account, BRM scores 5 out of 10 in our fundamental rating. BRM was compared to 50 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally BRM also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BRM had positive earnings in the past year.
In the past year BRM had a positive cash flow from operations.
In multiple years BRM reported negative net income over the last 5 years.
Each year in the past 5 years BRM had a positive operating cash flow.
1.2 Ratios
BRM has a Return On Assets (5.86%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 31.16%, BRM belongs to the top of the industry, outperforming 82.00% of the companies in the same industry.
With a decent Return On Invested Capital value of 13.26%, BRM is doing good in the industry, outperforming 70.00% of the companies in the same industry.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 14.75%.
The last Return On Invested Capital (13.26%) for BRM is above the 3 year average (10.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROIC | 13.26% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
Looking at the Profit Margin, with a value of 11.38%, BRM is in line with its industry, outperforming 54.00% of the companies in the same industry.
The Operating Margin of BRM (27.11%) is better than 76.00% of its industry peers.
In the last couple of years the Operating Margin of BRM has declined.
Looking at the Gross Margin, with a value of 74.69%, BRM is in the better half of the industry, outperforming 68.00% of the companies in the same industry.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
BRM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BRM has less shares outstanding than it did 1 year ago.
BRM has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.07 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BRM (2.07) is worse than 60.00% of its industry peers.
BRM has a debt to FCF ratio of 3.80. This is a good value and a sign of high solvency as BRM would need 3.80 years to pay back of all of its debts.
BRM has a Debt to FCF ratio of 3.80. This is comparable to the rest of the industry: BRM outperforms 60.00% of its industry peers.
BRM has a Debt/Equity ratio of 2.67. This is a high value indicating a heavy dependency on external financing.
BRM has a Debt to Equity ratio of 2.67. This is amonst the worse of the industry: BRM underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Altman-Z | 2.07 |
ROIC/WACC1.53
WACC8.66%
2.3 Liquidity
A Current Ratio of 1.28 indicates that BRM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.28, BRM is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
The Quick ratio of BRM (1.17) is better than 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 599.05%, which is quite impressive.
The earnings per share for BRM have been decreasing by -24.57% on average. This is quite bad
BRM shows a small growth in Revenue. In the last year, the Revenue has grown by 4.62%.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 36.74% on average per year.
The Revenue is expected to decrease by -5.02% on average over the next years.
EPS Next Y499.13%
EPS Next 2Y132.22%
EPS Next 3Y74.72%
EPS Next 5Y36.74%
Revenue Next Year-3.38%
Revenue Next 2Y-5.21%
Revenue Next 3Y-3.73%
Revenue Next 5Y-5.02%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 6.41, which indicates a rather cheap valuation of BRM.
Based on the Price/Earnings ratio, BRM is valued cheaper than 92.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.45. BRM is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.66, the valuation of BRM can be described as very cheap.
92.00% of the companies in the same industry are more expensive than BRM, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of BRM to the average of the S&P500 Index (21.90), we can say BRM is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.41 | ||
| Fwd PE | 7.66 |
4.2 Price Multiples
88.00% of the companies in the same industry are more expensive than BRM, based on the Enterprise Value to EBITDA ratio.
BRM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BRM is cheaper than 94.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.32 | ||
| EV/EBITDA | 6.32 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM's earnings are expected to grow with 74.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y132.22%
EPS Next 3Y74.72%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 5.32%, which is a nice return.
In the last 3 months the price of BRM has falen by -21.79%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
BRM's Dividend Yield is rather good when compared to the industry average which is at 3.03. BRM pays more dividend than 92.00% of the companies in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
5.2 History
On average, the dividend of BRM grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 90.59% of its income as dividend. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP90.59%
EPS Next 2Y132.22%
EPS Next 3Y74.72%
FRA:BRM (7/3/2025, 7:00:00 PM)
39.955
-0.95 (-2.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.11%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap81.31B
Analysts67.5
Price Target48.82 (22.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP90.59%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.45%
Min EPS beat(2)13.54%
Max EPS beat(2)19.36%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)13.54%
Max EPS beat(4)25.96%
EPS beat(8)7
Avg EPS beat(8)11.3%
EPS beat(12)11
Avg EPS beat(12)9.38%
EPS beat(16)15
Avg EPS beat(16)7.79%
Revenue beat(2)2
Avg Revenue beat(2)4.66%
Min Revenue beat(2)3.68%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)4.59%
Min Revenue beat(4)3.68%
Max Revenue beat(4)5.63%
Revenue beat(8)6
Avg Revenue beat(8)1.95%
Revenue beat(12)8
Avg Revenue beat(12)1.4%
Revenue beat(16)10
Avg Revenue beat(16)1.19%
PT rev (1m)-0.68%
PT rev (3m)-11.53%
EPS NQ rev (1m)-2.94%
EPS NQ rev (3m)-4.8%
EPS NY rev (1m)-1.73%
EPS NY rev (3m)0.26%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.41 | ||
| Fwd PE | 7.66 | ||
| P/S | 2.01 | ||
| P/FCF | 7.32 | ||
| P/OCF | 6.69 | ||
| P/B | 5.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.32 |
EPS(TTM)6.23
EY15.59%
EPS(NY)5.22
Fwd EY13.06%
FCF(TTM)5.46
FCFY13.66%
OCF(TTM)5.97
OCFY14.94%
SpS19.87
BVpS7.25
TBVpS-11.19
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.86% | ||
| ROE | 31.16% | ||
| ROCE | 18.89% | ||
| ROIC | 13.26% | ||
| ROICexc | 16.01% | ||
| ROICexgc | 72.41% | ||
| OM | 27.11% | ||
| PM (TTM) | 11.38% | ||
| GM | 74.69% | ||
| FCFM | 27.47% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.98%
ROICexgc(3y)70.34%
ROICexgc(5y)71.31%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-15.94%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.54%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 3.8 | ||
| Debt/EBITDA | 2.21 | ||
| Cap/Depr | 15.15% | ||
| Cap/Sales | 2.57% | ||
| Interest Coverage | 6.1 | ||
| Cash Conversion | 68.16% | ||
| Profit Quality | 241.48% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.07 |
F-Score7
WACC8.66%
ROIC/WACC1.53
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)599.05%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%140.91%
EPS Next Y499.13%
EPS Next 2Y132.22%
EPS Next 3Y74.72%
EPS Next 5Y36.74%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%-5.6%
Revenue Next Year-3.38%
Revenue Next 2Y-5.21%
Revenue Next 3Y-3.73%
Revenue Next 5Y-5.02%
EBIT growth 1Y22.52%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year282.44%
EBIT Next 3Y50.39%
EBIT Next 5Y24.24%
FCF growth 1Y18.09%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y17.06%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%